7015-25-0 Usage
General Description
NSC401904 is a chemical compound that belongs to the class of 3-(Substituted amino)-1H-indazoles. It is a potentially important drug candidate that has shown anti-proliferative activity against a wide range of cancer cell lines in preclinical studies. NSC401904 has also been found to have anti-inflammatory and analgesic properties in animal models, making it a promising candidate for the development of new therapeutic agents for cancer and inflammatory conditions. Further research is needed to fully understand its mechanisms of action and potential clinical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 7015-25-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,0,1 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 7015-25:
(6*7)+(5*0)+(4*1)+(3*5)+(2*2)+(1*5)=70
70 % 10 = 0
So 7015-25-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H14O2/c13-12(14)11-8-4-7-10(11)9-5-2-1-3-6-9/h1-3,5-6,10-11H,4,7-8H2,(H,13,14)
7015-25-0Relevant articles and documents
-
Zimmerman,H.E. et al.
, p. 6096 - 6108 (1968)
-
Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids
-
Page/Page column 22, (2008/06/13)
The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme w
8-substituted xanthines as selective adenosine receptor agents
-
, (2008/06/13)
Xanthine derivatives having general structure (I) including the (R) and (S) enantiomers and racemic mixtures thereof, and the pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are each independently (C 1 -C 4)lower alkyl or (C 2 -C 4)lower al
